vs
Side-by-side financial comparison of HUYA Inc. (HUYA) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
HUYA Inc. is the larger business by last-quarter revenue ($237.1M vs $177.4M, roughly 1.3× Pacira BioSciences, Inc.). Pacira BioSciences, Inc. runs the higher net margin — 1.6% vs 0.6%, a 1.1% gap on every dollar of revenue. Over the past eight quarters, HUYA Inc.'s revenue compounded faster (2.5% CAGR vs -0.2%).
HUYA Inc. is a leading interactive live streaming platform based in China, focused primarily on video game live broadcasting. It also offers esports events, variety entertainment, lifestyle and educational live streams, mainly serving young digital entertainment consumers in the domestic Chinese market.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
HUYA vs PCRX — Head-to-Head
Income Statement — Q3 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $237.1M | $177.4M |
| Net Profit | $1.3M | $2.9M |
| Gross Margin | 13.4% | — |
| Operating Margin | -0.8% | 3.9% |
| Net Margin | 0.6% | 1.6% |
| Revenue YoY | — | 5.0% |
| Net Profit YoY | — | — |
| EPS (diluted) | — | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | — | $196.9M | ||
| Q3 25 | $237.1M | $179.5M | ||
| Q2 25 | $218.8M | $181.1M | ||
| Q1 25 | $207.9M | $168.9M | ||
| Q4 24 | — | $187.3M | ||
| Q3 24 | $219.1M | $168.6M | ||
| Q2 24 | $212.1M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | — | — | ||
| Q3 25 | $1.3M | $5.4M | ||
| Q2 25 | $-766.0K | $-4.8M | ||
| Q1 25 | $128.0K | $4.8M | ||
| Q4 24 | — | — | ||
| Q3 24 | $3.4M | $-143.5M | ||
| Q2 24 | $4.1M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 79.5% | ||
| Q3 25 | 13.4% | 80.9% | ||
| Q2 25 | 13.5% | 77.4% | ||
| Q1 25 | 12.5% | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | 13.2% | 76.9% | ||
| Q2 24 | 13.9% | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | — | 1.2% | ||
| Q3 25 | -0.8% | 3.5% | ||
| Q2 25 | -1.5% | 4.7% | ||
| Q1 25 | -4.0% | 1.2% | ||
| Q4 24 | — | 13.2% | ||
| Q3 24 | -2.1% | -82.8% | ||
| Q2 24 | -1.7% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | — | — | ||
| Q3 25 | 0.6% | 3.0% | ||
| Q2 25 | -0.4% | -2.7% | ||
| Q1 25 | 0.1% | 2.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.5% | -85.1% | ||
| Q2 24 | 1.9% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | — | $0.05 | ||
| Q3 25 | — | $0.12 | ||
| Q2 25 | — | $-0.11 | ||
| Q1 25 | — | $0.10 | ||
| Q4 24 | — | $0.38 | ||
| Q3 24 | — | $-3.11 | ||
| Q2 24 | — | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $102.0M | $144.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $709.9M | $653.9M |
| Total Assets | $960.3M | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | — | $238.4M | ||
| Q3 25 | $102.0M | $246.3M | ||
| Q2 25 | $69.7M | $445.9M | ||
| Q1 25 | $40.9M | $493.6M | ||
| Q4 24 | — | $484.6M | ||
| Q3 24 | $156.1M | $453.8M | ||
| Q2 24 | $138.4M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | — | $693.1M | ||
| Q3 25 | $709.9M | $727.2M | ||
| Q2 25 | $704.3M | $757.8M | ||
| Q1 25 | $711.2M | $798.5M | ||
| Q4 24 | — | $778.3M | ||
| Q3 24 | $1.1B | $749.6M | ||
| Q2 24 | $1.3B | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | — | $1.3B | ||
| Q3 25 | $960.3M | $1.3B | ||
| Q2 25 | $928.0M | $1.5B | ||
| Q1 25 | $1.3B | $1.6B | ||
| Q4 24 | — | $1.6B | ||
| Q3 24 | $1.6B | $1.5B | ||
| Q2 24 | $1.6B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HUYA
| Live streaming | $162.5M | 69% |
| Game-related services, advertising and others | $74.7M | 31% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
